This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as pre­clin­i­cal and clin­i­cal studies testing new and existing treat­ments for myeloma.

During the session, research results were made avail­able for review by meeting attendees in the form …

Results from a recent Italian Phase 1/2 clinical trial indicate that the com­bi­na­tion of Pomalyst, cyclo­phos­pha­mide, and prednisone is effective and safe in re­lapsed and re­frac­to­ry multiple myeloma patients.

Overall, 51 percent of patients in the trial responded to the treat­ment, and the me­di­an pro­gres­sion-free survival time was 10.4 months. The me­di­an overall survival had not been reached yet; however, 69 percent of patients were alive one year after starting treat­ment.

The study participants had previously been treated with a me­di­an of three prior therapies, and all had re­ceived prior treatment with 

Final results from a Phase 3 study show that Pomalyst in combination with low-dose dexamethasone is effective for relapsed and refractory multiple myeloma patients not responding to treatment with Revlimid and Velcade.

Specifically, the results show that patients receiving Pomalyst (pomalidomide, Imnovid) in combination with low-dose dexamethasone (Decadron) had higher response rates and longer progression-free and overall survival than patients who received high-dose dexamethasone alone.

High-dose dexamethasone was chosen as the comparator in this study because, according to the study investigators, it was a common rescue treatment for …

Poma­lido­mide plus low-dose dexa­metha­sone dem­onstrated sig­nif­i­cantly longer median pro­gres­sion-free survival and over­all survival at a median follow-up of 10 months

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that updated results from MM-003, a phase III multi-center, ran­dom­ized open-label study (n=455) of poma­lido­mide (marketed as POMALYST^® in the U.S. and IMNOVID^® in the E.U.) plus low-dose dexa­metha­sone, were published online ahead of print in The Lancet Oncology.

The study compared oral poma­lido­mide plus low-dose dexa­metha­sone with high-dose dexa­metha­sone in patients with refractory or re­lapsed and refractory multiple myeloma who have failed at least two prior thera­pies with both bor­tez­o­mib and lena­lido­mide, ad­min­is­tered alone or in …

A new retrospective study provides insight into the benefit the new mye­lo­ma drugs Kyprolis and Pomalyst may provide to patients who are re­sis­tant to, or cannot tolerate, both Velcade and Revlimid.

The study's results highlight how challenging it can be to find an effective treat­ment for patients who are “dual refractory” (resistant to both Velcade and Rev­li­mid).

Patients in the study who received either Kyprolis (car­filz­o­mib) or Poma­lyst (poma­lido­mide, Imnovid) after becoming dual refractory had longer over­all survival than those who were not treated with the new drugs.

The …

Die Europäische Kommission (EC) hat Pomalidomid für die Behandlung von bestimmten Patienten mit multiplem Myelom zugelassen. Der europäische Markenname für die Substanz wird voraussichtlich "Imnovid" lauten, obwohl die endgültige Zulassung für diesen Namen noch aussteht.

In den Vereinigten Staaten wird Pomalidomid unter dem Markennamen Poma­lyst vertrieben. Es wurde zu Beginn des Jahres von der US-amerikanischen Food und Drug Administration (FDA) als neue Behandlung für das Myelom zugelassen.

Die EG hat Imnovid in Kombination mit Dexamethason für den Gebrauch bei Patienten mit multiplen Myelom zugelassen, die mindestens zwei Vortherapien, einschließlich Revlimid (Lenalidomid) und …

The European Commission (EC) has approved pomalidomide for the treatment of certain patients with multiple myeloma.  The European brand name for the drug is expected to be "Imnovid," although final regu­la­tory approval of that name is still pending.

In the United States, pomalidomide is marketed under the brand name Poma­lyst.  It was approved earlier this year by the U.S. Food and Drug Ad­min­is­tra­tion (FDA) as a new treatment for myeloma.

The EC approved Imnovid for use in combination with dexamethasone (Decadron) in patients with …